Everest Organics Ltd. Everest Organics Limited is a pharmaceutical company. The Company is engaged in the business of bulk drugs and active pharmaceutical ingredients (APIs). It is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen and Benzimadizole. Its products under APIs include Pantoprazole Sodium Sesquihydrate-USP/BP/EP/IP; Esomeprazole Magnesium Trihydrate-USP/BP/IP/EP; Esomeprazole Magnesium Trihydrate- USP/BP (Non-infringing route); Esomeprazole Magnesium Dihydrate; Omeprazole Powder-USP/ BP/EP/IP; Omeprazole Magnesium-IP/EP/USP, and Esomeprazole Sodium. Its intermediates include 2-Mercapto-5-Methoxy Benzimidazole (Omeprazole-Benzimidazole); 2-chloro-methyl-3, 5-dimethyl-4-methoxy pyridine HCL (Omeprazole Chloro Compound); Sodium Nitrite; Ammonium Sulphate, and Trisodium Orthophosphate (TSP). Its products under development includes Vildagliptin, Ilaprazole, Esomeprazole Magnesium Dihydrate, Lanso Chloro Compound and Lanso Sulphide.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.